[Federal Register Volume 87, Number 183 (Thursday, September 22, 2022)]
[Notices]
[Pages 57918-57919]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-20529]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Accelerating the Pace of Drug Abuse Research Using 
Existing Data.
    Date: October 27-28, 2022.
    Time: 11 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Li Rebekah Feng, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural 
Activities, National Institute on Drug Abuse, NIH, 301 North 
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-7245, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Increasing Immediate Engagement and Retention in HIV 
Treatment with Substance Users.
    Date: October 27, 2022.
    Time: 1 p.m. to 2 p.m.

[[Page 57919]]

    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Marisa Srivareerat, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Office of Extramural Policy, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 435-1258, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Coordinating Center for the HIV/AIDS and Substance 
Use Cohorts Program.
    Date: November 2, 2022.
    Time: 3 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Brian Stefan Wolff, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Research, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 480-1448, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Avenir Award Program for Chemistry and Pharmacology 
of Substance Use Disorders (DP1--Clinical Trial Allowed).
    Date: November 29, 2022.
    Time: 9:45 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Marisa Srivareerat, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Office of Extramural Policy, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 435-1258, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: September 16, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-20529 Filed 9-21-22; 8:45 am]
BILLING CODE 4140-01-P